CN109790223A - 用于治疗癌症的抗siglec-7抗体 - Google Patents

用于治疗癌症的抗siglec-7抗体 Download PDF

Info

Publication number
CN109790223A
CN109790223A CN201780060307.2A CN201780060307A CN109790223A CN 109790223 A CN109790223 A CN 109790223A CN 201780060307 A CN201780060307 A CN 201780060307A CN 109790223 A CN109790223 A CN 109790223A
Authority
CN
China
Prior art keywords
seq
antibody
siglec
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780060307.2A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·贝炳东
沃特·科沃尔
内纳德·托马斯维克
苏济·埃尔巴德
肯尼思·鲁尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arakos Co Ltd
Original Assignee
Arakos Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arakos Co Ltd filed Critical Arakos Co Ltd
Publication of CN109790223A publication Critical patent/CN109790223A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780060307.2A 2016-08-05 2017-08-04 用于治疗癌症的抗siglec-7抗体 Pending CN109790223A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371680P 2016-08-05 2016-08-05
US62/371,680 2016-08-05
PCT/US2017/045641 WO2018027203A1 (en) 2016-08-05 2017-08-04 Anti-siglec-7 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN109790223A true CN109790223A (zh) 2019-05-21

Family

ID=61073084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780060307.2A Pending CN109790223A (zh) 2016-08-05 2017-08-04 用于治疗癌症的抗siglec-7抗体

Country Status (13)

Country Link
US (1) US11773162B2 (https=)
EP (1) EP3494142A4 (https=)
JP (1) JP7137563B2 (https=)
KR (1) KR20190035863A (https=)
CN (1) CN109790223A (https=)
AU (1) AU2017307616A1 (https=)
BR (1) BR112019002331A2 (https=)
CA (1) CA3032437A1 (https=)
EA (1) EA201990296A1 (https=)
IL (1) IL264674B2 (https=)
MX (1) MX2019001471A (https=)
SG (1) SG11201901020RA (https=)
WO (1) WO2018027203A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7137563B2 (ja) 2016-08-05 2022-09-14 アラコス，インコーポレイティド がん治療用の抗Ｓｉｇｌｅｃ－７抗体
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
AU2018298673A1 (en) 2017-07-10 2019-12-19 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019140273A1 (en) * 2018-01-11 2019-07-18 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20230210989A1 (en) * 2020-06-03 2023-07-06 Kar Muthumani Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
JP2025027841A (ja) * 2023-08-17 2025-02-28 国立大学法人 東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120815A2 (en) * 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
CN101687924A (zh) * 2007-07-04 2010-03-31 株式会社未来创药研究所 抗Muc17抗体
CN105073133A (zh) * 2012-12-21 2015-11-18 Aveo制药公司 抗gdf15抗体
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
US20160115231A1 (en) * 2013-05-21 2016-04-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
MX383594B (es) 2014-08-07 2025-03-14 Daiichi Sankyo Co Ltd Anticuerpo anti-orai1.
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
WO2017123745A1 (en) 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
WO2017153433A1 (en) 2016-03-08 2017-09-14 Innate Pharma Siglec neutralizing antibodies
JP7137563B2 (ja) 2016-08-05 2022-09-14 アラコス，インコーポレイティド がん治療用の抗Ｓｉｇｌｅｃ－７抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120815A2 (en) * 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
CN101687924A (zh) * 2007-07-04 2010-03-31 株式会社未来创药研究所 抗Muc17抗体
CN105073133A (zh) * 2012-12-21 2015-11-18 Aveo制药公司 抗gdf15抗体
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANDUS等: "Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance", 《THE JOURNAL OF CLINICAL INVESTIGATION》, vol. 124, no. 4, 24 February 2014 (2014-02-24), pages 1810 - 1820 *

Also Published As

Publication number Publication date
EP3494142A4 (en) 2020-04-01
JP7137563B2 (ja) 2022-09-14
MX2019001471A (es) 2019-10-30
EP3494142A1 (en) 2019-06-12
AU2017307616A1 (en) 2019-02-28
IL264674A (https=) 2019-03-31
JP2019526622A (ja) 2019-09-19
WO2018027203A1 (en) 2018-02-08
KR20190035863A (ko) 2019-04-03
SG11201901020RA (en) 2019-03-28
EA201990296A1 (ru) 2019-08-30
BR112019002331A2 (pt) 2019-06-18
IL264674B2 (en) 2023-09-01
US20190194323A1 (en) 2019-06-27
US11773162B2 (en) 2023-10-03
CA3032437A1 (en) 2018-02-08
IL264674B1 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
CN109790223A (zh) 用于治疗癌症的抗siglec-7抗体
TWI803637B (zh) 特異性針對gucy2c之抗體及其用途
CN112566935B (zh) 抗ox40抗体和使用方法
ES2777603T3 (es) Anticuerpos PD-L1 ("ligando de muerte programada 1")
CN113929782B (zh) 对淋巴细胞中抑制途径的中和
CN112566937B (zh) 对cd3特异性的抗体及其用途
CN108738324A (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
IL296874A (en) Antibodies specific for the human poliovirus receptor
CN108136003A (zh) 抗pd-1和抗m-csf抗体在癌症治疗中的联合应用
ES2959504T9 (es) Anticuerpos anti-CD38 para el tratamiento de la leucemia linfoblástica aguda
TW202035445A (zh) 抗lap抗體變異體及其用途
CN110431152A (zh) 抗gitr抗体及其使用方法
JP7342005B2 (ja) エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体
AU2021308586A1 (en) Therapeutic antibodies and their uses
EP4305073A1 (en) Anti-human cxcr5 antibody and uses thereof
CN114641500A (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
TW202523694A (zh) 抗muc16抗體及其用途
CA3000400C (en) Agonistic antibodies specifically binding human cd40 and methods of use
CN121620534A (zh) 抗tigit抗体及其用途
HK40113788A (zh) 抗cd39抗体及其用途
HK40046552A (en) Antibodies specific for cd3 and uses thereof
HK40050839A (en) Anti-ox40 antibodies and methods of use
BR112017005178B1 (pt) Uso de um anticorpo que neutraliza a atividade inibidora de nkg2a humano

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190521

WD01 Invention patent application deemed withdrawn after publication